Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy

HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that data from preclinical studies of its HER2-targeted CAR-T cell containing its dual-switch technology will be

Bellicum Pharmaceuticals Announces Closing of Public Offering

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc.(NASDAQ:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares

Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc.(NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its